Orexo´s Nomination Committee for the Annual General Meeting 2024

Rhea-AI Summary

Orexo appoints Nomination Committee for the upcoming Annual General Meeting in 2024. The committee will prepare proposals for various positions and fees, and shareholders can submit their proposals by February 24, 2024.

Positive

• The Nomination Committee represents approximately 35% of the votes in the company.
• The committee will prepare proposals for Chairman of the meeting, Chairman of the Board, Board members, Board member fees, remuneration for committee work, fees to the auditor, and principles for the composition of the Nomination Committee.

Negative

• None.

UPPSALA, Sweden, Oct. 26, 2023 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2024, that will take place on April 26, a Nomination Committee has been appointed. The shareholders having appointed members of the Nomination Committee represent approximately 35 percent of the number of votes in the company, based on the latest known shareholder information. The Nomination Committee consists of:

• Henrik Kjaer Hansen, (chairman, appointed by Novo Holdings A/S)
• Claus Berner Møller, (appointed by ATP)^[1]
• Robert Florczykowski, (appointed by Third Dot)^[2]
• James Noble, (chairman of the board of Orexo)

The Nomination Committee will prepare proposals to the AGM regarding Chairman of the meeting, Chairman of the Board, Board members, Board member fees, any remuneration for committee work, and fees to the auditor, as well as principles for the composition of the Nomination Committee.

The Nomination Committee's proposals will be presented in the Notice of the AGM and on Orexo's website, www.orexo.com. Shareholders who want to submit proposals to the Nomination Committee can do this by sending an e-mail to ir@orexo.com (subject "Nomination Committee") at latest February 24, 2024.

Orexo AB (publ.)

Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2022 amounted to SEK 624 million, and the number of employees to 126. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow X, (former Twitter), LinkedIn, and YouTube.

^[1] The Danish Labour Market Supplementary Pension
[2] Third Dot´s shareholding in Orexo is registered in a foreign nominee's name, but is confirmed by Euroclear via voting right registration ahead of the extraordinary general meeting on October 26, 2023, and amounted to 705 421 shares

The information was submitted for publication at 5 pm CET on October 26, 2023.

The following files are available for download:

https://mb.cision.com/Main/694/3863741/2389480.pdf

Orexo´s Nomination Committee for the Annual General Meeting 2024

 

View original content:https://www.prnewswire.com/news-releases/orexos-nomination-committee-for-the-annual-general-meeting-2024-301968999.html

SOURCE Orexo

FAQ

When is the Annual General Meeting scheduled for?

The Annual General Meeting is scheduled for April 26, 2024.

What will the Nomination Committee prepare proposals for?

The Nomination Committee will prepare proposals for Chairman of the meeting, Chairman of the Board, Board members, Board member fees, remuneration for committee work, fees to the auditor, and principles for the composition of the Nomination Committee.

How can shareholders submit proposals to the Nomination Committee?

Shareholders can submit proposals to the Nomination Committee by sending an e-mail to ir@orexo.com with the subject 'Nomination Committee' by February 24, 2024.